T1	Participants 53 92	type 2 diabetes inadequately controlled
T2	Participants 297 410	Patients inadequately controlled [glycated haemoglobin (HbA1c) >7 to ≤10% (>53 to ≤86 mmol/mol)] on basal insulin
T3	Participants 455 483	empagliflozin 10 mg (n = 169
T4	Participants 486 515	empagliflozin 25 mg (n = 155)
T5	Participants 519 549	placebo (n = 170) for 78 weeks
